||ORD SHS 10P
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Hikma Pharmaceuticals Share Discussion Threads
Showing 501 to 525 of 525 messages
|One step at a time. Let's break through £20.60 first then £21.|
|Still looking positive.
Last Signal:STAY LONG
Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 01/02/2017, 19 days ago, when the stock price was 1,848.0000. Since then HIK.L has risen by +10.06%.
As of Feb 18, 2017, the consensus forecast amongst 12 polled investment analysts covering Hikma Pharmaceuticals Plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jun 30, 2016. The previous consensus forecast advised investors to purchase equity in Hikma Pharmaceuticals Plc.
Broker Forecasts - January 2017
Peel Hunt 25/01 Initiates/starts Buy 2,340.00p
JP Morgan Cazenove 17/01 Reiterates Overweight 2,100.00p|
|Indeed, as happened, and now onwards....................
I will be continuing to hold at present since there is still plenty of potential in my opinion.|
|I expect £20 threshold to be broken today.|
|No shorting here - just following the Directors faith in the company. Also The Capital Group Companies, have gone above 10% ownership threshold. These are all good signs as is the Easyhaler deal just signed with Orion.|
|Good news and time to move up.|
|Haha! Is that a deliberate ploy to tempt fate? Have you shorted them? G2theary made a similar comment a couple of weeks back - right before they fell to 1800! Fingers crossed!|
|Nice healthy rise today. Well on course for the 2,000 level!|
|trump statement on big pharm was yesterday's big news.|
|West-Ward Columbus announced the addition of 95 jobs by 2020 to staff an expansion of its pharmaceutical manufacturing facility as well as a warehouse under construction in Obetz, Ohio, according to an article in Columbus Business First.The expansion is for additions to the company's line of generic drugs made at the division of Hikma Pharmaceuticals Plc. Hikma is continuing plans for growth made under former owner Boehringer Ingelheim, the story said.About 65 added technician jobs are expected by the end of 2020 to staff a 30,300-square-foot, two-story addition to the west Columbus plant. West-Ward also is building a 276,000-square-foot distribution facility in Obetz that will create another 30 jobs, according to the article.|
|Some large buys today:-
16:35 - 31/01
Buy 343782 1,824.00p £6,270,583.68
13:19 - 31/01
Buy 151325 1,809.00p £2,737,469.25
13:19 - 31/01
Buy 151000 1,809.00p £2,731,590.00
Keep the faith!|
|Yes, I wonder who was selling. We'll see how it goes tomorrow.|
|Picked up a few just before close, bit of blind optimism that the sell-off may have run its course. Then 2 massive sales go through after close! Not looking good for the morning. I still think there's value in these, but the magic 2000 seems a way off right now - to think it seemed a certainty just over a week ago. Just hope they don't edge 16/1700.|
|Agreed. Its not a share for widows and orphans!|
|thanks for that up date interesting will hold for the next few months see how it goes but this is a roller coaster of a share. Still in the top 100 so that helps as well Most of the brokers have this as a buy as well and given the large take over a year ago should see some good news flow but can never tell with this share. My only share in this sector|
|No idea when next trading statement will be but full years figures should be available in March.
Darhold appears to be a vehicle for Directors etc to hold shares in Hikma. An old Guardian article (May 2015)at https://www.theguardian.com/business/marketforceslive/2015/may/11/hikma-higher-on-buy-note-and-acquisition-prospects
included the quote:-
"The Jordanian-based company has expanded rapidly over the past few years by building a world-class injectable generics business and enjoyed strong growth as a branded pharma player in its home MENA markets. Following the recent decline in Hikma’s share price, the company now trades at a 10% 2015 PER discount to its peers. We believe the sell-off is overdone, and we are therefore upgrading our recommendation to Buy.
Any reticence to consider Hikma seems to primarily be concerned with Hikma’s roots as a Jordanian, family-run company with a large operation in the Middle East. However, with the family controlling 28.8% of the company through their Darhold Ltd stake, management interests are well aligned with the shareholders.
We believe large acquisitions are possible in the near future and will remain an integral part of Hikma’s business plan...."
As I said before, it is a bumpy ride, but one where the largest shareholders are prepared to put their money where their mouth is!|
|I had this share last year and sold at a profit but not before it gone up 50% then down again. Any idea when the next trading statement is as the last two have not been kind to the shares. Sorry who Darhold do they hold 25% of the comany and who behind them thanks
If could get past 20 that be good|
|This is a bit of a bumpy ride, but latest broker forecast (Peel Hunt) on 25 January has an assessment of "Buy" with a target of 2340. I'll be in to at least 2000 and hopefully higher. This will move very quickly if there is further good news or renewed massive purchases from Darhold Limited who already own over 25%.|
|Pharma with generic medicines should do better in Trump world as their medicines are cheaper.|
|Shardview - It's up to you to take a profit if you wish. I'm going to be holding at present and seeking a level of 2,000.|
|Anyone getting a bit nervous that, at least in the short/medium term, these may have peaked? They're some distance from their 1575 floor and there seems to be a fair bit of negativity around pharma at present.|
|Nice.......I suspect its DARHOLD LTD again!!!!|
|145000 buy with a premium at close.|
|News - 18 January - Hikma receives approval for Sodium Oxybate Oral Solution
London, 18 January 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its wholly owned US subsidiary, Roxane Laboratories, Inc. (Roxane), has received an approval from the US Food and Drug Administration for its Sodium Oxybate Oral Solution, 500 mg/mL, the generic equivalent to Xyrem®. Roxane's Sodium Oxybate Oral Solution is indicated for the treatment of cataplexy (sudden loss of muscle strength) and excessive daytime sleepiness in patients with narcolepsy.|
Going nicely today........|